Search

Displaying results 3121 - 3130 of 7479 in total
  1. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    It is an experimental therapy that is being developed by NeoRx Corporation.

  2. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  3. Drug

    Chlorpropamide

    go.drugbank.com/drugs/DB00672
    ApprovedWithdrawn

    Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. … Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

    Products: ANTI-D TABLET 250 mg
  4. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

  5. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durval...

  6. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat has a monoisotopic molecular weight of 608.14 Da. … Frespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With

  7. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...

  8. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Mixtures: Semprex-D, Semprex D
  9. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

  10. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Lir...